Human Plasma Distribution of Free Paclitaxel and Paclitaxel Associated with Diblock Copolymers
- 30 April 1997
- journal article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 86 (4), 460-464
- https://doi.org/10.1021/js960333n
Abstract
Amphiphilic diblock copolymer poly (D,L-lactide)-block-methoxy polyethylene glycol was synthesized, and paclitaxel (Taxol) was incorporated into this copolymer above its critical micelle concentration (cmc), resulting in the formation of polymeric micellar paclitaxel (PMT). Free paclitaxel dissolved in acetonitrile (TAX) and PMT, at 10 micrograms of paclitaxel/mL of human plasma, were incubated for 5, 30, and 60 min at 37 degrees C. Following incubation, the plasma was separated into its high-density (HDL), low-density (LDL), very-low-density (VLDL) lipoprotein and lipoprotein-deficient (LPDP) plasma fractions by density gradient ultracentrifugation. Each of these lipoprotein (LP) and LPDP fractions were analyzed for paclitaxel and plasma lipid levels by well-established HPLC and enzymatic assays. When TAX was incubated in human plasma for 5 min, an equal amount of drug was found in the LP and LPDP fractions. This distribution profile did not change following incubation for 30 and 60 min. Of the amount of TAX that was distributed within the LP fraction, 70-75% of TAX was associated with the HDL fraction for all time points studied. The paclitaxel plasma and LP distribution profile for PMT was similar to the distribution profile of TAX, suggesting that the plasma and LP distribution of paclitaxel is independent of the method of paclitaxel delivery and that LP distribution is not a function of mass lipid levels.Keywords
This publication has 26 references indexed in Scilit:
- Effects of Cremophor EL on distribution of Taxol to serum lipoproteinsBritish Journal of Cancer, 1994
- Pharmacology and Toxicology of Cremophor EL DiluentAnnals of Pharmacotherapy, 1994
- Pharmaceutical Issues: Preparation, Administration, Stability, and Compatibility with other MedicationsAnnals of Pharmacotherapy, 1994
- A Mixed Micellar Formulation Suitable for the Parenteral Administration of TaxolPharmaceutical Research, 1994
- Measurement of Cremophor EL Following Taxol: Plasma Levels Sufficient to Reverse Drug Exclusion Mediated by the Multidrug-Resistant PhenotypeJNCI Journal of the National Cancer Institute, 1993
- Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1993
- Block copolymer micelles as vehicles for drug deliveryJournal of Controlled Release, 1993
- Mechanism of action of taxolTrends in Pharmacological Sciences, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Unusual Serum Lipoprotein Abnormality Induced by the Vehicle of MiconazoleNew England Journal of Medicine, 1977